Novo Nordisk A/S (NYSE:NVO) Position Increased by Pathstone Holdings LLC

Pathstone Holdings LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 290,229 shares of the company’s stock after buying an additional 734 shares during the period. Pathstone Holdings LLC’s holdings in Novo Nordisk A/S were worth $34,558,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Davis R M Inc. acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $201,000. Vaughan David Investments LLC IL purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $227,000. Pitcairn Co. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $1,915,000. Natixis grew its holdings in shares of Novo Nordisk A/S by 748.1% during the 1st quarter. Natixis now owns 5,903 shares of the company’s stock valued at $758,000 after acquiring an additional 5,207 shares in the last quarter. Finally, Crewe Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the first quarter worth $50,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 1.9 %

Shares of NVO stock opened at $99.82 on Tuesday. The stock’s 50 day simple moving average is $117.94 and its 200 day simple moving average is $129.42. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $447.95 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.